Program

Oct. 16-17, 2024, Wyndham Philadelphia Historic District

Registration, Poster Check In, Breakfast
7:30 – 8:30 a.m.

Welcome, Opening Remarks
8:30 – 8:35 a.m.

New Cancer-specific Antigens and Targeting of Intracellular Oncoproteins
8:35 – 10:20 a.m.

Daniel Powell, PhD, University of Pennsylvania
New cancer-specific antigens and targeting of intracellular oncoproteins, CAR-based
Johanna Olweus, MD, PhD, Oslo University Hospital
New cancer-specific antigens and targeting of intracellular oncoproteins, TCR-based
Sebastian Amigorena, PhD, Mnemo Therapeutics
Targeting the “dark genome”
Panel Discussion + Q&A

Break
10:20 – 10:50 a.m.

Keynote Presentation – The Future of CAR-T Cells in Solid Tumors
10:50 – 11:50 a.m.

Lunch + Exhibits
11:50 a.m. – 12:50 p.m.

Rational Combinations with Genetically Engineered Cells
12:55 – 2:10 p.m.

Leyuan Ma, PhD, University of Pennsylvania
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Richard Vile, PhD, Mayo Clinic
Oncolytic viruses in combination with CAR-T cells
Panel Discussion

Break
2:10 – 2:20 p.m.

CAR Integration and T Cell Malignancies
2:20 – 3:40 p.m.

Frederic Bushman, University of Pennsylvania
The biology and consequences of lentiviral integration: From HIV to engineered immune cells
Steven Schuster, MD, University of Pennsylvania
Incidence of secondary malignancies in patients receiving CAR-T for lymphoma
Panel Discussion

Break
3:40 – 4:10 p.m.

Abstracts
4:10 – 5:25 p.m.

Poster Viewing and Networking Reception
5:30 – 6:45 p.m.

Off the Shelf CAR-T Cells Using Direct In Vivo
8:30 – 10:15 a.m.

Break
10:15 -10:45 a.m.

Abstracts
10:45 a.m. – 12 p.m.

Closing Remarks
12 – 12:10 p.m.